Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Nash P.Kirkham B.Okada M.Rahman P.Combe B.Burmester G.-R.Adams D.H.Kerr L.Lee C.Shuler C.L.Genovese M.Ahmed K.Alper J.Barkham N.Bennett R.E.Garc?a F.J.B.Alonso R.B.Blumstein H.B.Brooks M.S.Burmester G.-R.Cagnoli P.Caldron P.H.Cantagrel A.Chen D.-Y.Churchill M.A.Jr, Codding C.E.Codding C.E.JrCombe B.Deane P.M.G.Del Giudice J.Deodhar A.A.Dhar R.K.Dokoupilova E.Egan R.M.Everding A.Gal?ndez E.Genovese M.Goddard D.H.Gottlieb A.Goupille P.Griffin R.M.Gupta R.C.Hall S.Hatti K.Howell M.P.Huang Y.-H.Jajoo R.Janssen N.M.Kiltz U.Kivitz A.J.Klein S.J.Korkosz M.P.Kotha R.Kremer J.M.Lue C.de la Fuente J.L.M.Marzo-Ortega H.Masmitja J.G.Mease P.J.Meroni P.L.Mueller E.C.Nandagudi A.C.Nash P.Fern?ndez-Nebro A.Neuwelt C.M.Orbai A.M.Oza M.R.Parks D.L.Pattanaik D.Rell-Bakalarska M.E.Rosmarin D.Roussou E.Rychlewska-Hanczewksa A.I.Sikes D.H.Stack M.T.Sunkureddi P.Tahir H.Tha?i D.TSEN-FANG TSAITurkiewicz A.M.Unger L.Cabello R.V.Wagner U.Wei C.-C.Wells A.F.Youssef P.Zielinska A.2020-10-222020-10-2220170140-6736https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019588667&doi=10.1016%2fS0140-6736%2817%2931429-0&partnerID=40&md5=236ff8571826ca4e66f9637a2c529079https://scholars.lib.ntu.edu.tw/handle/123456789/517580Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialjournal article10.1016/S0140-6736(17)31429-0285510732-s2.0-85019588667